ImmuCell Corporation
ICCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $26,493 | $17,472 | $18,568 | $19,243 |
| % Growth | 51.6% | -5.9% | -3.5% | – |
| Cost of Goods Sold | $18,552 | $13,075 | $10,919 | $10,587 |
| Gross Profit | $7,941 | $4,396 | $7,649 | $8,656 |
| % Margin | 30% | 25.2% | 41.2% | 45% |
| R&D Expenses | $3,899 | $4,395 | $4,494 | $4,169 |
| G&A Expenses | $2,217 | $2,134 | $2,264 | $1,726 |
| SG&A Expenses | $5,683 | $5,223 | $5,454 | $4,230 |
| Sales & Mktg Exp. | $3,466 | $3,088 | $3,190 | $2,504 |
| Other Operating Expenses | $0 | $527 | $0 | $0 |
| Operating Expenses | $9,581 | $10,144 | $9,948 | $8,399 |
| Operating Income | -$1,640 | -$5,748 | -$2,299 | $257 |
| % Margin | -6.2% | -32.9% | -12.4% | 1.3% |
| Other Income/Exp. Net | -$506 | -$22 | -$187 | -$327 |
| Pre-Tax Income | -$2,147 | -$5,770 | -$2,486 | -$69 |
| Tax Expense | $10 | $5 | $8 | $9 |
| Net Income | -$2,157 | -$5,775 | -$2,494 | -$78 |
| % Margin | -8.1% | -33.1% | -13.4% | -0.4% |
| EPS | -0.26 | -0.75 | -0.32 | -0.01 |
| % Growth | 65.3% | -134.4% | -3,006.8% | – |
| EPS Diluted | -0.26 | -0.75 | -0.32 | -0.01 |
| Weighted Avg Shares Out | 8,167 | 7,699 | 7,745 | 7,592 |
| Weighted Avg Shares Out Dil | 8,167 | 7,748 | 7,745 | 7,592 |
| Supplemental Information | – | – | – | – |
| Interest Income | $78 | $0 | $153 | $19 |
| Interest Expense | $569 | $0 | $349 | $314 |
| Depreciation & Amortization | $2,687 | $2,717 | $2,488 | $2,461 |
| EBITDA | $1,067 | -$2,504 | $350 | $2,699 |
| % Margin | 4% | -14.3% | 1.9% | 14% |